### **HYDROXYCHLOROQUINE Drug Specific Monitoring Document**



TARGET	Board-wide
AUDIENCE	
PATIENT GROUP	All patients aged 12 years and older taking
	Hydroxychloroquine

#### References

- British National Formulary (2024). BNF / NICE. [online] NICE. Available at: https://bnf.nice.org.uk/.
- Specialist Pharmacy Service (2021). *Medicines Monitoring*. [online] SPS Specialist Pharmacy Service. Available at: <a href="https://www.sps.nhs.uk/home/tools/drug-monitoring/">https://www.sps.nhs.uk/home/tools/drug-monitoring/</a>.
- Electronic Medicines Compendium (2019). *Home electronic medicines compendium (emc)*. [online] Medicines.org.uk. Available at: <a href="https://www.medicines.org.uk/emc">https://www.medicines.org.uk/emc</a>
- Yusuf, I.H., Foot, B. and Lotery, A.J. (2021). The Royal College of Ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): executive summary. *Eye*, 35(6), pp.1532–1537. <a href="https://doi.org/10.1038/s41433-020-01380-2">https://doi.org/10.1038/s41433-020-01380-2</a>

### Governance information for drug specific document

Lead Author(s):	Medicines Policy and Guidance Team
Endorsing Body:	Area Drug and Therapeutics Committee
Version Number:	V1.1
Approval date	18.06.2025
Review Date:	18.06.2026
Responsible Person (if different from lead author)	Kirsty Macfarlane/Mark Russell

# **HYDROXYCHLOROQUINE Drug Specific Monitoring Document**

Medication	HYDROXYCHLOROQUINE	
Name		
Actions by	• LFTs	
specialist	Blood pressure	
clinician	Full blood count	
before	Height & Weight (Ideal body weight used for dosing)	
initiation		
Initiation	• eGFR	
	For all drugs, specialist clinicians should consider whether vaccination/exclusion of other	
	contraindications (including active infection), is required and arrange as appropriate.	
DIS actions on	This box is intentionally blank.	
starting	, , , , , , , , , , , , , , , , , , , ,	
treatment		
and following		
dose titration		
during		
initiation		
period		
Ongoing	Annually - where patient has been taking hydroxychloroquine for >5yrs or risk	
monitoring in	factors as described below; check patient is referred to and attending	
Primary Care	ophthalmology annually.	
once stable	Annual monitoring (including fundus autofluorescence and spectral domain optical	
	coherence tomography) is recommended in all patients who have taken	
	hydroxychloroquine for longer than 5 years	
	Annual monitoring may be started before 5 years of treatment if additional risk	
	factors for retinotoxicity exist, such as concomitant tamoxifen therapy, impaired renal	
	function (eGFR less than 60 mL/minute/1.73 m²), or high-dose therapy (more than	
	5 mg/kg/day of hydroxychloroquine sulfate.	
	Ophthalmological examinations must be repeated at least every 12 months.	
Action if	Consult specialist team for any further guidance	
monitoring is		
outside		
reference		
range		
Actions to	Actions may vary. Consult specialist team for any further guidance	
take if		
restarting	Patients should be referred by the specialist clinician to the drug initiation hub if re-	
medication	titration or enhanced monitoring is required	
after		
treatment		
break		

Uncontrolled when printed - access the most up to date version on www.nhslguidelines.scot.nhs.uk

Lead Author	Kirsty Macfarlane/Mark Russell	Date approved	18.06.2025
Version	V1.1	Review Date	18.06.2026

# **HYDROXYCHLOROQUINE Drug Specific Monitoring Document**

CONSULTATION AND DISTRIBUTION RECORD		
Contributing Author / Authors	Kirsty Macfarlane, Mark Russell, Kendal Paterson, Katrina Maroni	
Consultation Process / Stakeholders:	LMC, GP Sub-committee, Karen Donaldson Eimear Gordon, Anthony Carson, Richard Shearer, Rebecca Malley, Rosemary Beaton, Drug Initiation Service pharmacists, Acute specialist dermatology and rheumatology consultants and pharmacists.	
Distribution	Acute specialist consultants and pharmacists, Senior primary care pharmacists, all individuals involved with the Drug Initiation Service, LMC and GP sub-committee	

CHANGE RECORD			
Date	Lead Author	Change	Version

Uncontrolled when printed - access the most up to date version on www.nhslguidelines.scot.nhs.uk

Lead Author	Kirsty Macfarlane/Mark Russell	Date approved	18.06.2025
Version	V1.1	Review Date	18.06.2026